Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Clinical trial NCT04392505 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04392505
Sponsor: Oslo University Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer Non Small Cell Lung Cancer Non Small Cell Lung Cancer Stage III NSCLC NSCLC, Stage III

Start date: 2020-05-11
Primary completion: 2025-05-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.